Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: Systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 17-24

  Cataldo, Maria Adriana ^a   Tacconelli, Evelina ^b   Grilli, Elisabetta ^a   Pea, Federico ^c   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antimicrobial treatment; Continuous infusion; Gram positive infections; Intermittent infusion; MRSA; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; CEPHALOSPORIN; MONOBACTAM; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CONTINUOUS INFUSION; DEPRESSION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INFUSION; GRAM POSITIVE INFECTION; HUMAN; KIDNEY INJURY; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; OBSERVATIONAL STUDY; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEADY STATE; SYSTEMATIC REVIEW; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; METHODOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; RENAL INSUFFICIENCY; VANCOMYCIN;

EID: 84859170733     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr442     Document Type: Article

References (36)

1. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
2. Beibei L, Yun C, Mengli C et al. Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010; 35: 3-12.
3. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomialpneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139: 1148-55.
4. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): ameta-analysis. Curr Med Res Opin 2010; 26: 407-21.
5. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923-9.
6. Cai Y, Wang R, Liang B et al. Effectiveness and safety of tigecycline for the treatment of infectious disease: a systematic review and meta-analysis. Antimicrob Agents Chemother 2011; 55: 1162-72.
7. Bliziotis IA, Plessa E, Peppas G et al. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis. Ann Pharmacother 2010; 44: 97-106.
8. McClaine RJ, Husted TL, Hebbeler-Clark RS et al. Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clin Infect Dis 2010; 50: 1120-6.
9. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8
10. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
11. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
12. Löwdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998; 42:2739-44.
13. Aeschlimann JR, Hershberger E, Rybak MJ. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1914-8.
14. Knudsen JD, Fuursted K, Raber S et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247-54.
15. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-42.
16. Roberts JA, Lipman J, Blot S et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14: 390-6.
17. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008; 47: 147-52.
18. Rello J, Sole-Violan J, Sa-Borges M et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005;33:1983-7.
19. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
20. Wysocki M, Thomas F, Wolff MA et al. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother 1995; 35: 352-4.
21. Di Filippo A, De Gaudio AR, Novelli A et al. Continuous infusion of vancomycin in methicillin-resistant Staphylococcus infection. Chemotherapy 1998; 44: 63-8.
22. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
23. Vuagnat A, Stern R, Lotthe A et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004; 29: 351-7.
24. Hutschala D, Kinstner C, Skhirdladze K et al. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 2009; 111: 356-65.
25. Ingram PR, Lye DC, Fisher DA et al. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009; 34: 570-4.
26. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006;12: 92-5.
27. Jarutanasirikul S, Julamanee J, Sudsai T et al. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus. J Med Assoc Thai 2010; 93: 172-6.
28. James JK, Palmer SM, Levine DP et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696-700.
29. Klepser ME, Patel KB, Nicolau DP et al. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 1998; 18: 1069-74.
30. EPOC Data Collection Checklist. http://epoc.cochrane.org/epoc-resources-review-authors (30 June 2011, date last accessed).
31. Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2005. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (30 May 2011, date last accessed)
32. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
33. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
34. Lassnigg A, Schmidlin D, Mouhieddine M et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. JAmSoc Nephrol 2004; 15: 1597-605.
35. Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
36. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.